 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | RAG-01 / Ractigen Therap
Enrollment open: A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Gu (clinicaltrials.gov) - Apr 16, 2024
P1, N=15, Recruiting, Sponsor: Ractigen Therapeutics.
Not yet recruiting --> Recruiting
- | RAG-01 / Ractigen Therap
New P1 trial: A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Gu (clinicaltrials.gov) - Apr 8, 2024
P1, N=15, Not yet recruiting, Sponsor: Ractigen Therapeutics.
- RAG01-40-31L / Ractigen Therap
Preclinical development of RAG1-40-31L: A novel small activating RNA-lipid conjugate targeting tumor suppressor gene p21 for treatment of non-muscle invasive bladder cancer. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_5404;
The C5X5 lipid conjugate appears to be a viable approach to enhance oligonucleotide delivery and activity in bladder cancer. Preclinical safety assessment studies to enable clinical trials of RAG01-40-31L are currently underway.